Extension Study to the "Open-label Phase I Study Evaluating the Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs - The COOPERATE-1 Study".
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Everolimus (Primary) ; Pasireotide (Primary)
- Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Adverse reactions
- Acronyms COOPERATE-1
- Sponsors Novartis Pharmaceuticals
- 03 Oct 2017 Planned End Date changed from 31 Oct 2017 to 1 May 2020.
- 03 Oct 2017 Planned primary completion date changed from 31 Oct 2017 to 1 May 2020.
- 20 Apr 2016 Planned End Date changed from 1 Apr 2016 to 1 Oct 2017.